The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk
Open accessAbstract
Significance: Macrophage-mediated programmed cell removal (PrCR) plays an essential role in tumor surveillance and elimination. Blockade of the don't-eat-me signal CD47 on tumor cells allows already expressed eat-me signals to induce PrCR to eliminate tumor cells. To date the molecular mechanism by which macrophages recognize and phagocytose tumor cells remains unclear. This paper demonstrates that the activation of Toll-like receptor (TLR) pathways in macrophages induces the phosphorylation of Bruton's tyrosine kinase (Btk), which catalyzes cell-surface exposure of calreticulin. Calreticulin on or secreted by macrophages plays a critical role in mediating adjacent tumor cell recognition and phagocytosis. These findings reveal a strategy to enhance the efficacy of PrCR through a combination of TLR/Btk activation and CD47 blockade, and advance our understanding of the underlying mechanism of macrophage-mediated PrCR of tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Role of CD47 as a Marker of Self on Red Blood Cells
Oldenborg, P.-A., Zheleznyak, A., Fang, Y.-F., Lagenaur, C. F., Gresham, H. D., & Lindberg, F. P. (2000) · Science · doi:10.1126/science.288.5473.2051 · Cited by 1,970
Kawai, T., & Akira, S. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401850 · Cited by 1,810
The history of toll-like receptors - redefining innate immunity
O'Neill, L. A. J., Golenbock, D., & Bowie, A. G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3446 · Cited by 1,765 · cited 1×
“pathogens (20, 21), and TLR agonists are listed as immunotherapeutic agents with anticancer potential (22).”
BackgroundMajeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
Self-citationWillingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121623109 · Cited by 1,666
Self-citationCD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,581
Self-citationBRUTON, O. C. (1952) · Pediatrics · doi:10.1542/peds.9.6.722 · Cited by 1,492
Gardai, S. J., McPhillips, K. A., Frasch, S. C., Janssen, W. J., Starefeldt, A., Murphy-Ullrich, J. E., Bratton, D. L., Oldenborg, P.-A., Michalak, M., & Henson, P. M. (2005) · Cell · doi:10.1016/j.cell.2005.08.032 · Cited by 1,473
Ogden, C. A., deCathelineau, A., Hoffmann, P. R., Bratton, D., Ghebrehiwet, B., Fadok, V. A., & Henson, P. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.781 · Cited by 1,147
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087
Self-citationChao, M. P., Jaiswal, S., Weissman-Tsukamoto, R., Alizadeh, A. A., Gentles, A. J., Volkmer, J., Weiskopf, K., Willingham, S. B., Raveh, T., Park, C. Y., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001375 · Cited by 776
Self-citationTseng, D., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Fathman, J. W., Fernhoff, N. B., Seita, J., Inlay, M. A., Weiskopf, K., Miyanishi, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305569110 · Cited by 657
Self-citationA transcription activator-like effector toolbox for genome engineering
Sanjana, N. E., Cong, L., Zhou, Y., Cunniff, M. M., Feng, G., & Zhang, F. (2012) · Nature Protocols · doi:10.1038/nprot.2011.431 · Cited by 627
PI3K and negative regulation of TLR signaling
Fukao, T., & Koyasu, S. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00139-x · Cited by 612
Vandivier, R. W., Ogden, C. A., Fadok, V. A., Hoffmann, P. R., Brown, K. K., Botto, M., Walport, M. J., Fisher, J. H., Henson, P. M., & Greene, K. E. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3978 · Cited by 516
Mohamed, A. J., Yu, L., Bäckesjö, C., Vargas, L., Faryal, R., Aints, A., Christensson, B., Berglöf, A., Vihinen, M., Nore, B. F., et al. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00741.x · Cited by 511
Lim, K.-H., & Staudt, L. M. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a011247 · Cited by 469
Identification and manipulation of tumor associated macrophages in human cancers
Heusinkveld, M., & van der Burg, S. H. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-216 · Cited by 435
Therapeutic Antibody Targeting of CD47 Eliminates Human Acute Lymphoblastic Leukemia
Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C. Y., Weissman, I. L., & Majeti, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2238 · Cited by 382
Self-citationbcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages.
Lagasse, E., & Weissman, I. L. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.1047 · Cited by 274
Self-citationEdris, B., Weiskopf, K., Volkmer, A. K., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Liu, J., Majeti, R., West, R. B., Fletcher, J. A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121629109 · Cited by 258
Self-citationAnti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
Kim, D., Wang, J., Willingham, S. B., Martin, R., Wernig, G., & Weissman, I. L. (2012) · Leukemia · doi:10.1038/leu.2012.141 · Cited by 249
Self-citationMacrophages as mediators of tumor immunosurveillance
Jaiswal, S., Chao, M. P., Majeti, R., & Weissman, I. L. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.04.001 · Cited by 246
Self-citationProgrammed cell removal: a new obstacle in the road to developing cancer
Chao, M. P., Majeti, R., & Weissman, I. L. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3171 · Cited by 245
Self-citationChao, M. P., Tang, C., Pachynski, R. K., Chin, R., Majeti, R., & Weissman, I. L. (2011) · Blood · doi:10.1182/blood-2011-02-338020 · Cited by 194
Self-citationBAP-135, a target for Bruton’s tyrosine kinase in response to B cell receptor engagement
Yang, W., & Desiderio, S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.604 · Cited by 175
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
Burger, J. A., & Buggy, J. J. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.777837 · Cited by 170
Regulation of the phospholipase C‐γ2 pathway in B cells
(2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.00605.x · Cited by 160
Signaling by Toll-like Receptors 8 and 9 Requires Bruton's Tyrosine Kinase
Doyle, S., Jefferies, C. A., Feighery, C., & O'Neill, L. A. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707682200 · Cited by 151
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response
Lee, K.-G., Xu, S., Kang, Z.-H., Huo, J., Huang, M., Liu, D. X., Takeuchi, O., Akira, S., & Lam, K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119238109 · Cited by 150
Theocharides, A. P. A., Jin, L., Cheng, P.-Y., Prasolava, T. K., Malko, A. V., Ho, J., Poeppl, A. G., van Rooijen, N., Minden, M. D., Danska, J. S., et al. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120502 · Cited by 139
Jabir, M. S., Ritchie, N. D., Li, D., Bayes, H. K., Tourlomousis, P., Puleston, D. J., Lupton, A., Hopkins, L., Simon, A. K., Bryant, C. E., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.01.010 · Cited by 113
Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
Brown, J. R. (2013) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0147-9 · Cited by 108
Bruton's Tyrosine Kinase is a Key Regulator in B‐Cell Development
Rawlings, D. J., & Witte, O. N. (1994) · Immunological Reviews · doi:10.1111/j.1600-065x.1994.tb00849.x · Cited by 106
Mori, K., Hiroi, M., Shimada, J., & Ohmori, Y. (2011) · Cancers · doi:10.3390/cancers3043726 · Cited by 96
Bruton’s Tyrosine Kinase Is Required for TLR-Induced IL-10 Production
Schmidt, N. W., Thieu, V. T., Mann, B. A., Ahyi, A.-N. N., & Kaplan, M. H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7203 · Cited by 91
Transcription Factor STAT5A Is a Substrate of Bruton's Tyrosine Kinase in B Cells
Mahajan, S., Vassilev, A. O., Sun, N., Özer, Z., Mao, C., & Uckun, F. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104874200 · Cited by 65
Anticancer TLR agonists on the ropes
Guha, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3775 · Cited by 58
Byrne, J. C., Gabhann, J. N., Stacey, K., Coffey, B. M., McCarthy, E. M., Thomas, W., & Jefferies, C. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300057 · Cited by 58
Al, A., Kanegane, H., Miyawaki, T., & Mm, V. (2003) · PubMed · Cited by 54
X-Linked Agammaglobulinemia and Bruton’s Tyrosine Kinase
Tsukada, S., & Witte, O. N. (1994) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-0987-9_24 · Cited by 13
TLR-induced activation of Btk – Role for endosomal MHC class II molecules revealed
Gabhann, J. N., & Jefferies, C. A. (2011) · Cell Research · doi:10.1038/cr.2011.88 · Cited by 13
Cited by
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
Phagocytosis checkpoints as new targets for cancer immunotherapy
Feng, M., Jiang, W., Kim, B. Y. S., Zhang, C. C., Fu, Y.-X., & Weissman, I. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0183-z · Cited by 911
Self-citationMechanisms of immunotherapy resistance: lessons from glioblastoma
Jackson, C. M., Choi, J., & Lim, M. (2019) · Nature Immunology · doi:10.1038/s41590-019-0433-y · Cited by 751
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer
Li, C., Xu, X., Wei, S., Jiang, P., Xue, L., & Wang, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001341 · Cited by 360
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Roschewski, M., Lionakis, M. S., Sharman, J. P., Roswarski, J., Goy, A., Monticelli, M. A., Roshon, M., Wrzesinski, S. H., Desai, J. V., Zarakas, M. A., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd0110 · Cited by 357
Metadata
- Authors
- Feng, M., Chen, J. Y., Weissman-Tsukamoto, R., Volkmer, J.-P., Ho, P. Y., McKenna, K. M., Cheshier, S., Zhang, M., Guo, N., Gip, P., Mitra, S. S., & Weissman, I. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2015-02-02
- Volume
- 112
- Issue
- 7
- Pages
- 2145-2150
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2169550645
- Cited by
- 253
- References
- 44
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.